[go: up one dir, main page]

CL2012000159A1 - Procedimiento para la preparacion estereoselectiva de compuestos (trans)- y (cis)-9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, y los compuestos intermediarios considerados. - Google Patents

Procedimiento para la preparacion estereoselectiva de compuestos (trans)- y (cis)-9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, y los compuestos intermediarios considerados.

Info

Publication number
CL2012000159A1
CL2012000159A1 CL2012000159A CL2012000159A CL2012000159A1 CL 2012000159 A1 CL2012000159 A1 CL 2012000159A1 CL 2012000159 A CL2012000159 A CL 2012000159A CL 2012000159 A CL2012000159 A CL 2012000159A CL 2012000159 A1 CL2012000159 A1 CL 2012000159A1
Authority
CL
Chile
Prior art keywords
compounds
procedure
undecan
quinazolin
diaza
Prior art date
Application number
CL2012000159A
Other languages
English (en)
Inventor
Guenther Huchler
Markus Ostermeier
Juergen Daeubler
Stephan Kling
Marco Santagostino
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2012000159A1 publication Critical patent/CL2012000159A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACIÓN ESTEREOSELECTIVA DE COMPUESTOS DE LAS FÓRMULAS (LA) Y (LB) Y DEL COMPUESTO INTERMEDIARIO DE FÓRMULA (18); YA LOS COMPUESTOS INTERMEDIARIOS DE FÓRMULA (4), (5), (6), (12), (13) Y (22).<br />  
CL2012000159A 2009-08-06 2012-01-19 Procedimiento para la preparacion estereoselectiva de compuestos (trans)- y (cis)-9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, y los compuestos intermediarios considerados. CL2012000159A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09167393A EP2289881A1 (de) 2009-08-06 2009-08-06 Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen

Publications (1)

Publication Number Publication Date
CL2012000159A1 true CL2012000159A1 (es) 2012-08-31

Family

ID=41205591

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000159A CL2012000159A1 (es) 2009-08-06 2012-01-19 Procedimiento para la preparacion estereoselectiva de compuestos (trans)- y (cis)-9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, y los compuestos intermediarios considerados.

Country Status (21)

Country Link
US (2) US8658790B2 (es)
EP (2) EP2289881A1 (es)
JP (1) JP2013501025A (es)
KR (1) KR20120049248A (es)
CN (1) CN102471288B (es)
AR (1) AR077797A1 (es)
AU (1) AU2010280852B2 (es)
BR (1) BR112012002104A2 (es)
CA (1) CA2767963A1 (es)
CL (1) CL2012000159A1 (es)
DK (1) DK2462126T3 (es)
EA (1) EA023562B1 (es)
ES (1) ES2549770T3 (es)
HU (1) HUE025400T2 (es)
IL (1) IL216969A (es)
MX (1) MX2012001089A (es)
NZ (1) NZ597698A (es)
PL (1) PL2462126T3 (es)
TW (1) TW201120013A (es)
UY (1) UY32830A (es)
WO (1) WO2011015526A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289881A1 (de) * 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen
EA023573B1 (ru) * 2011-02-01 2016-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Дималеат 9-[4-(3-хлор-2-фторфениламино)-7-метоксихиназолин-6-илокси]-1,4-диазаспиро[5.5]ундекан-5-она, его применение в качестве лекарственного средства и его получение
JP6105631B2 (ja) 2012-02-09 2017-03-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，４−保護９−ヒドロキシ−５−オキソ−１，４−ジアザ−スピロ［５．５］ウンデカンの立体選択的合成方法
JP2015524400A (ja) * 2012-07-19 2015-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンのフマル酸塩、その薬物としての使用及び調製
EP4126847A1 (en) 2020-03-30 2023-02-08 ENYO Pharma Quinazolinone derivatives and uses thereof for treating a cancer
US11680403B2 (en) * 2020-09-21 2023-06-20 Amp Ip Llc Multi-purpose structural panels and systems for assembling structures

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US7998949B2 (en) * 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
HRP20120696T1 (hr) * 2007-10-26 2012-10-31 Japan Tobacco, Inc. Spiro-prstenasti spoj i njegova medicinska upotreba
BRPI0907916A2 (pt) * 2008-02-07 2015-07-28 Boehringer Ingelheim Int Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
EP2313377B1 (de) * 2008-08-08 2016-01-06 Boehringer Ingelheim International Gmbh Verfahren zur stereoselektiven synthese bicyclischer heterocyclen
EP2289881A1 (de) * 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen
EA023573B1 (ru) 2011-02-01 2016-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Дималеат 9-[4-(3-хлор-2-фторфениламино)-7-метоксихиназолин-6-илокси]-1,4-диазаспиро[5.5]ундекан-5-она, его применение в качестве лекарственного средства и его получение
JP6105631B2 (ja) * 2012-02-09 2017-03-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，４−保護９−ヒドロキシ−５−オキソ−１，４−ジアザ−スピロ［５．５］ウンデカンの立体選択的合成方法

Also Published As

Publication number Publication date
IL216969A (en) 2015-06-30
EA023562B1 (ru) 2016-06-30
IL216969A0 (en) 2012-02-29
NZ597698A (en) 2014-03-28
EA201200219A1 (ru) 2012-11-30
TW201120013A (en) 2011-06-16
EP2462126B1 (de) 2015-07-15
UY32830A (es) 2011-03-31
EP2462126A1 (de) 2012-06-13
KR20120049248A (ko) 2012-05-16
CA2767963A1 (en) 2011-02-10
HUE025400T2 (en) 2016-02-29
CN102471288A (zh) 2012-05-23
AU2010280852B2 (en) 2015-04-02
BR112012002104A2 (pt) 2015-09-15
MX2012001089A (es) 2012-02-28
US20140135495A1 (en) 2014-05-15
WO2011015526A1 (de) 2011-02-10
DK2462126T3 (en) 2015-09-07
US8658790B2 (en) 2014-02-25
PL2462126T3 (pl) 2015-11-30
AR077797A1 (es) 2011-09-21
ES2549770T3 (es) 2015-11-02
JP2013501025A (ja) 2013-01-10
US8993753B2 (en) 2015-03-31
AU2010280852A1 (en) 2012-02-09
US20110183987A1 (en) 2011-07-28
CN102471288B (zh) 2014-10-22
EP2289881A1 (de) 2011-03-02

Similar Documents

Publication Publication Date Title
CO6630154A2 (es) Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos
MA37756A1 (fr) Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
TR201802791T4 (tr) Aril ve heteroaril füzyonlu laktamlar.
TN2012000575A1 (en) Compositions and methods for modulating the wnt signaling pathway
CO6852084A2 (es) Nuevos compuestos sustituidos con halógeno
EA201171062A1 (ru) Алкиламидные соединения и их применение
CL2012000159A1 (es) Procedimiento para la preparacion estereoselectiva de compuestos (trans)- y (cis)-9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, y los compuestos intermediarios considerados.
UY32292A (es) Agonistas de s1p1 y métodos de preparación y uso
MA35664B1 (fr) Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
UY32940A (es) Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
EA201200741A1 (ru) Способ получения этексилата дабигатрана
UY32142A (es) Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
DOP2010000047A (es) Compuestos de pirazol y su uso como inhibidores de raf
MA37940A2 (fr) Nouveaux dérivés bicycliques
CU24039B1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
ECSP11011244A (es) Nuevos herbicidas.
MX2010001837A (es) Derivados de 4-pirimidinasulfamida.
EA201070876A1 (ru) Трициклические соединения, обладающие антагонистической активностью по отношению к кортикотропин-высвобождающему фактору, и содержащие их фармацевтические композиции
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
MX344911B (es) Compuestos de eter amido-piridilico y composiciones y su uso contra parasitos.
MX346980B (es) Nuevos compuestos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona.
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MA38559B1 (fr) Dérivés d&#39;imidazo-triazine utilisés comme inhibiteurs de la pde10
EA201290610A1 (ru) Сульфоновые соединения в качестве лигандов 5-htрецептора